Trials that use: Multiple imputation / missing data
New to this method? Read the tutorial →
15,424 results
- Erector Spinae Block for Spine Surgery: Complete Statistical AnalysisIndependent statistical analysis of Erector Spinae Block for Spine Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05417113).
- Erector Spinae Plane vs. Paravertebral Nerve Block for Thoracic Surgery: Complete Statistical AnalysisIndependent statistical analysis of Erector Spinae Plane vs. Paravertebral Nerve Block for Thoracic Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03758261).
- EREPIndependent statistical analysis of Emotion Regulation and Emotion Perception: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03790878).
- ERGO2Independent statistical analysis of Calorie-restricted, Ketogenic Diet and Transient Fasting During Reirradiation for Patients With Recurrent Glioblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Eribulin in HER2 Negative Metastatic BrCa: Complete Statistical AnalysisIndependent statistical analysis of Eribulin in HER2 Negative Metastatic BrCa: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01827787).
- Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients: Complete Statistical AnalysisIndependent statistical analysis of Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction: Complete Statistical AnalysisIndependent statistical analysis of Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer: Complete Statistical AnalysisIndependent statistical analysis of Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- ErivedgeIndependent statistical analysis of Vismodegib for Treatment of Basal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01543581).
- Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Erlotinib and Chemotherapy for Patients With Stage IB-IIIA NSCLC With EGFR Mutations (ECON): Complete Statistical AnalysisIndependent statistical analysis of Erlotinib and Chemotherapy for Patients With Stage IB-IIIA NSCLC With EGFR Mutations (ECON): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer: primary endpoint results, effect estimate with confidence interval, sample-size…
- Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00476476).
- Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2: primary endpoint results, effect estimate with…
- Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00970502).
- ERPIndependent statistical analysis of Treatment Response of Geriatric Depression: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00754936).
- Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005): Complete Statistical AnalysisIndependent statistical analysis of Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02099110).
- Ertugliflozin: Cardioprotective Effects on Epicardial Fat: Complete Statistical AnalysisIndependent statistical analysis of Ertugliflozin: Cardioprotective Effects on Epicardial Fat: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04167761).
- Erythromycin in Parkinson’s Disease: Complete Statistical AnalysisIndependent statistical analysis of Erythromycin in Parkinson's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02005029).
- Erythropoietic Protoporphyrias: Studies of the Natural History, Genotype-Phenotype Correlations, and Psychosocial Impact: Complete Statistical AnalysisIndependent statistical analysis of Erythropoietic Protoporphyrias: Studies of the Natural History, Genotype-Phenotype Correlations, and Psychosocial Impact: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- ESBA1008 Microvolume Study: Complete Statistical AnalysisIndependent statistical analysis of ESBA1008 Microvolume Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01849692).
- ESBA105 in Patients With Severe Dry Eye: Complete Statistical AnalysisIndependent statistical analysis of ESBA105 in Patients With Severe Dry Eye: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01338610).
- EscapeIndependent statistical analysis of Clobetasol Propionate 0.05% Shampoo in Association With Antifungal Shampoo in Scalp Seborrheic Dermatitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- ESCAPEIndependent statistical analysis of Evaluation of Stepped Care for Chronic Pain in Iraq/Afghanistan Veterans (ESCAPE): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- ESCAPeIndependent statistical analysis of Extended Steroid in Use in Community Acquired Pneumonia (CAP)(e): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01283009).
- ESCAPE-TRDIndependent statistical analysis of A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major…
- ESCAPEDIndependent statistical analysis of Comparison of Patient Centered Outcomes for People With Sickle Cell Disease in the Acute Care Setting: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Escitalopram Effects on CSF Amyloid Beta: Complete Statistical AnalysisIndependent statistical analysis of Escitalopram Effects on CSF Amyloid Beta: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02161458).
- Escitalopram to Placebo in Patients With Localized Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Escitalopram to Placebo in Patients With Localized Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05289830).
- eSETIndependent statistical analysis of eSET Plus Single Embryo Cryotransfer vs Double Embryo Transfer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01909570).
- ESETTIndependent statistical analysis of Established Status Epilepticus Treatment Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01960075).
- ESkAPEIndependent statistical analysis of Enhancing Skeletal Adaptations to PTH and Exercise: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05029128).
- Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children: Complete Statistical AnalysisIndependent statistical analysis of Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Esmolol for Treatment of Perioperative Tachycardia: Complete Statistical AnalysisIndependent statistical analysis of Esmolol for Treatment of Perioperative Tachycardia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01208402).
- Esmolol or Nitroglycerin Infusion for Blood Pressure Control Prior to Cardiopulmonary Bypass (CPB) in Cardiac Surgery: Complete Statistical AnalysisIndependent statistical analysis of Esmolol or Nitroglycerin Infusion for Blood Pressure Control Prior to Cardiopulmonary Bypass (CPB) in Cardiac Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Esmolol vs. Labetalol in Endoscopic Sinus Surgery: Complete Statistical AnalysisIndependent statistical analysis of Esmolol vs. Labetalol in Endoscopic Sinus Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03661346).
- Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus: Complete Statistical AnalysisIndependent statistical analysis of Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- ESP Block for Post Cesarean Analgesia: Complete Statistical AnalysisIndependent statistical analysis of ESP Block for Post Cesarean Analgesia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05664958).
- ESP Block VS Intrathecal Opioid After Laparoscopic Colorectal Surgery: Complete Statistical AnalysisIndependent statistical analysis of ESP Block VS Intrathecal Opioid After Laparoscopic Colorectal Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05257941).